E-mail Article

MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.

* From Email:

* To Email:

To Email:

Email Subject Line:

Comments:

A double blind Placebo Controlled randomised Trial of Adalimumab in the treatment of Hidradenitis Suppurativa

Miller I et al. – A significant reduction was seen in Sartorius after 6 weeks and an almost significant reduction was seen after 12 weeks of active treatment when compared to the placebo–group. Significant reduction in Hidradenitis Suppurativa severity was gained after 6 weeks. No long–term curative effect was uniformly seen. [more...]

British Journal of Dermatology

Author Commentary Exclusive

I. Miller 04/12/2011
In this pilot randomised clinical trial we present further evidence supporting the efficacy of TNF alpha blockage in hidradenitis suppurativa

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Medical Student Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?